• Moderna (NasdaqGS:MRNA) is developing an early-stage mRNA vaccine candidate targeting hantavirus.
• Interest in the program has increased following a recent hantavirus outbreak linked to a cruise ship.
• The company is working with partners including the US Army Medical Research Institute of Infectious Diseases and Korea University.

For investors tracking Moderna beyond its COVID-19 franchise, the renewed focus on its hantavirus program adds another data point to the broader mRNA story. The stock closed at $52.88, with the share price up 71.4% year to date and up 105.8% over the past year, while still down 59.4% over three years and down 67.0% over five years. This mix of recent strength and longer term pressure shapes how some investors may think about risk and potential in NasdaqGS:MRNA.

The hantavirus project highlights how Moderna is trying to build out a wider infectious disease portfolio that is not limited to seasonal shots. As clinical data and any future regulatory milestones emerge, investors may pay attention to how these kinds of early programs contribute to the story of more diversified revenue sources over time.

Stay updated on the most important news stories for Moderna by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Moderna.

Investor Checklist

Quick Assessment

• ❌ Price vs Analyst Target: At US$52.88, the stock trades about 22% above the US$43.37 analyst price target, with a published range of US$21 to US$69.
• ⚖️ Simply Wall St Valuation: Simply Wall St's DCF view is not available, so there is no clear undervalued or overvalued signal from that model.
• ✅ Recent Momentum: A 3.8% 30 day return suggests short term positive momentum as attention picks up on the hantavirus program.

There is only one way to know the right time to buy, sell or hold Moderna. Head to Simply Wall St's company report for the latest analysis of Moderna's Fair Value.

Key Considerations

• 📊 The hantavirus work shows Moderna using its mRNA platform beyond COVID 19, which some investors may see as important for the future breadth of the pipeline.
• 📊 Watch updates on early clinical data, any regulatory feedback, and how analysts adjust revenue and earnings forecasts as this and other infectious disease programs progress.
• ⚠️ Execution risk in early stage vaccine development is high, and the stock is already trading above the consensus target, so expectations around new programs may be sensitive to any setbacks.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Moderna analysis. Alternatively, you can check out the community page for Moderna to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.